SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 during trading on the BSE.

A company official confirmed this effectively meant, the drug candidate was being discontinued. At 12.26 pm on Wednesday, SPARC shares were at down -18.25 per cent at ₹159.90.

Sun Pharma's shares experienced a 0.47 per cent decline, trading at Rs 1,659.80, alongside the sharper fall in SPARC shares to Rs 156.50 on the BSE.

Pryderi ap Rhisiart, managing director, M-SParc, said: "Our collaboration with Life Sciences Hub Wales has already been instrumental in delivering impactful initiatives such as the Health+ programme ...

In the fourth quarter of FY25 (Q4FY25), SPARC announced total earnings of Rs 20.96 crore, reflecting a 38.8 per cent rise from Rs 15.10 crore in Q3FY25.

Modest setback for Sun Pharma, 18% fall in SPARC shares as drug fails to deliver SPARC, the R&D arm of Sun Pharma, was testing SCD-044 for two auto-immune indications in a Phase-2 trial. Though ...

SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company will halt further development and assess next steps ...

The Association of University Teachers (AUT) Tamil Nadu demanded not to give re-employment to preferred teachers in Periyar University and immediately stop the approval given to an agenda by the ...

Sparc Technologies Limited (SPN), an ASX-listed company, is a South Australian-based company focused on developing and commercializing innovative technology for sustainable applications. A major focus ...

Sparc Electrex is trading at 6.83 as on Mon Jun 30 2025 07:33:51. This is 4.92 % upper as compared to its previous closing price of 6.51. What is the market capitalization of Sparc Electrex?

Nifty Steady Above 24,600; snaps 3-day losing streak. Midcaps outperform; market breadth positive. India VIX cools over 4%. Gains Led By Metals, IT; Realty slips, Banks consolidate. Catch Nandita ...